Little more than two weeks after commencing a European phase III trial of AM-101 in patients with acute peripheral tinnitus, Auris Medical AG has now begun a North American phase III study of the drug. Results from the two trials are expected next year, and, if positive, they could form the basis of regulatory submissions on either side of the Atlantic during the first quarter of 2016.
Janssen Biotech, Inc. is putting its foot on the gas in the development of Genmab A/S’s anti-CD38 multiple myeloma antibody daratumumab. Although it does not yet have any final phase II data in hand, it feels sufficiently emboldened by what it’s seen so far to move the drug into an extensive-phase pivotal program.
STOCKHOLM – Stockholm’s transition to a 21st century location for discovery science and drug development is under way in earnest, as two separate research partnerships between Astrazeneca plc and the Karolinska Institute start to gather momentum, while a preclinical drug development “toolbox,” aimed at academic researchers, will put out a call for its first projects in the coming months.
STOCKHOLM – The vexed problem of conclusively proving – or disproving – the amyloid hypothesis as the key driver of the pathology of Alzheimer’s disease has been exhaustively rehearsed in multiple settings over the last decade.
With phase III data from ulcerative colitis DNA-based drug Kappaproct (DIMS0150) due in the coming months, Index Pharmaceuticals AB has added $20 million to its balance sheet in advance.
Shares in Thrombogenics NV surged 15.5 percent during trading Monday, as the company unveiled plans to explore its “strategic options” – investment-bank speak for finding a deal or finding a buyer.
Advanced Accelerator Applications SA (AAA) added €41 million (US$56 million) to its coffers in a private equity round led by HBM Healthcare Investments Ltd., which put up €20 million of the total.
Synaffix BV closed a series A round to take forward its antibody-drug conjugation (ADC) technology, which offers a fresh take on the problem of ADC heterogeneity.
Shares in Karo Bio AB dropped 13 percent Thursday on news that the company was raising SEK84.7 million (US$13.1 million) in a heavily discounted share issue.
Carrot juice has long been celebrated for its healthy vitamin and mineral content, but for Gaucher disease patients, a genetically engineered form of the drink could have life-saving properties.
